

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE SUBJECT TO LEGAL RESTRICTIONS. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER TO BUY SECURITIES IN THE COMPANY. SEE ALSO THE SECTION "IMPORTANT INFORMATION" BELOW.

Magle Group raises approximately SEK 36.8 million in the rights issue

The Board of Directors of Magle Chemoswed Holding AB ("Magle Group" or the "Company") today, on 20 December 2024, announces the outcome of the rights issue of shares, announced by the Company on 22 November 2024 (the "Rights Issue"). In total, 1,148,544 shares were subscribed for with the support of subscription rights, corresponding to approximately 93.6 percent of the Rights Issue. Additionally, 426,616 shares, corresponding to approximately 34.8 percent of the Rights Issue, have been applied to be subscribed for without the support of subscription rights. In aggregate, the subscriptions with and without the support of subscription rights correspond to approximately 128.4 percent of the Rights Issue. As the Rights Issue has been oversubscribed, no guarantee commitments will be utilized. The Rights Issue will provide the Company with gross proceeds of approximately SEK 36.8 million before deduction of costs related to the Rights Issue. Out of the gross proceeds, approximately SEK 31.9 million is obtained through set-off of debts.

Outcome of the Rights Issue

The subscription period for the Rights Issue ended on 18 December 2024 and the outcome shows that the Rights Issue was subscribed for to approximately 128.4 percent, with and without the support of subscription rights. The Rights Issue comprised of no more than 1,226,794 shares, of which 1,148,544 shares, corresponding to approximately 93.6 percent of the Rights Issue, have been subscribed for with the support of subscription rights. Additionally, 426,616 shares, corresponding to approximately 34.8 percent of the Rights Issue, have been applied to be subscribed for without the support of subscription rights. In aggregate, the subscriptions with and without the support of subscription rights correspond to approximately 128.4 percent of the Rights Issue. As the Rights Issue has been oversubscribed, no guarantee commitments will be utilized. The Rights Issue will provide the Company with gross proceeds of approximately SEK 36.8 million before deduction of costs related to the Rights Issue. Out of the gross proceeds, approximately SEK 31.9 million is obtained through set-off of debts.

Number of shares and share capital

Following registration of the Rights Issue with the Swedish Companies Registration Office (Sw. *Bolagsverket*), the Company's share capital will increase by SEK 61,339.70 through the issuance of 1,226,794 new shares, corresponding to a dilution effect of approximately 6.2 percent for current shareholders that have not participated in the Rights Issue.

Notice of allotment

Those who have subscribed for shares without the support of subscription rights will be allocated shares in accordance with the allocation principles set out in the prospectus published by the Company on 2 December 2024. Notice of allotment to the persons who subscribed for shares without the support of subscription rights is expected to be distributed not later than 23 December 2024. Subscribed and allotted shares shall be paid in cash in accordance with the instructions on the settlement note sent to the subscriber. Subscribers who have subscribed through a nominee will receive notification of allocation in accordance with their respective nominee's procedures. Only those who have been allotted shares in the Rights Issue will be notified.

Advisors

Vator Securities is the financial advisor and issuer agent and Advokatfirman Schjødt is the legal advisor to Magle Group in connection with the Rights Issue.

For enquiries, please contact:

Magle Group
Justin Pierce, CEO
Email: justin.pierce@maglechemoswed.com
Telephone: +46 (0)70 593 58 21

About Magle Group

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise, Magle PharmaCept – an established sales and marketing company for development and direct sales of the Group's medical technology products and Magle Biopolymers A/S – a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com, www.maglegroup.com, www.maglepharmaceut.com and www.maglebiopolymers.com.

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Important information

Publication, release or distribution of this press release may in certain jurisdictions be subject to legal restrictions and persons in the jurisdictions where this press release has been made public or distributed should be informed of and follow such legal restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer or solicitation to buy or subscribe for any securities in Magle Group in any jurisdiction, either from Magle Group or from anyone else.

This press release is not a prospectus according to the definition in Regulation (EU) 2017/1129 (the “**Prospectus Regulation**”) and has not been approved by any regulatory authority in any jurisdiction. Any acquisition of shares in the rights issue should only be made on the basis of the information contained in the formal prospectus and supplementary prospectuses issued in connection with the rights issue and are held available on the Company's website, <https://maglegroup.com>.

This press release does not constitute an offer or solicitation to buy or subscribe for securities in the United States. The securities mentioned herein may not be sold in the United States without registration, or without an exemption from registration, under the U.S. Securities Act from 1933 (“**Securities Act**”), and may not be offered or sold within the United States without being registered, covered by an exemption from, or part of a transaction that is not subject to the registration requirements according to the Securities Act. There is no intention to register any securities mentioned herein in the United States or to issue a public offering of such securities in the United States. The information in this press release may not be released, published, copied, reproduced or distributed, directly or indirectly, wholly or in part, in or to United States, Australia, Belarus, Hong Kong, Japan, Canada, New Zealand, Russia, Singapore, South Africa, South Korea or any other jurisdiction where the release, publication or distribution of this information would violate current rules or where such an action is subject to legal restrictions or would require additional registration or other measures beyond those that follow from Swedish law. Actions in contravention of this instruction may constitute a violation of applicable securities legislation.

Forward-looking statements

This press release contains forward-looking statements related to the Company's intentions, estimates or expectations with regard to the Company's future results, financial position, liquidity, development, outlook, estimated growth, strategies and opportunities as well as the markets in which the Company is active. Forward-looking statements are statements that do not refer to historical facts and can be identified by the use of terms such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “will,” “may,” “implies,” “should,” “could” and, in each case, their negative, or comparable terminology. The forward-looking statements in this press release are based on various assumptions, which in several cases are based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there is no guarantee that they will occur or that they are correct. Since these assumptions are based on assumptions or estimates and involve risks and uncertainties, actual results or outcomes, for many different reasons, may differ materially from those what is stated in the forward-looking statements. Due to such risks, uncertainties, eventualities and other significant factors, actual events may differ materially from the expectations that expressly or implicitly are contained in this press release through the forward-looking statements. The Company does not guarantee that the assumptions which serve as a basis for the forward-looking statements in this press release are correct, and each reader of the press release should not rely on the forward-looking statements in this press release. The information, opinions and forward-looking statements that expressly or implicitly are stated herein are provided only as of the date of this press release and may change. Neither the Company nor any other party will review, update, confirm or publicly announce any revision of any forwardlooking statement to reflect events that occur or circumstances that arise with respect to the contents of this press release, beyond what is required by law or Nasdaq First North Growth Market Rulebook.

This information is information that Magle Chemoswed is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-12-20 15:30 CET.

Attachments

[Magle Group raises approximately SEK 36.8 million in the rights issue](#)